{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:27:03Z","timestamp":1792168023537,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/purpose<\/jats:title>\n                    <jats:p>\n                      Lack of robust, feasible, and quantitative outcomes impedes Raynaud phenomenon (RP) clinical trials in systemic sclerosis (SSc) patients. Hyperspectral imaging (HSI) non-invasively measures oxygenated and deoxygenated hemoglobin (oxyHb and deoxyHb) concentrations and oxygen saturation (O\n                      <jats:sub>2<\/jats:sub>\n                      sat) in the skin and depicts data as oxygenation heatmaps. This study explored the potential role of HSI in quantifying SSc-RP disease severity and activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with SSc-RP (\n                      <jats:italic>n<\/jats:italic>\n                      = 13) and healthy control participants (HC;\n                      <jats:italic>n<\/jats:italic>\n                      = 12) were prospectively recruited in the clinic setting. Using a hand-held camera, bilateral hand HSI (HyperMed\u2122, Waltham, MA) was performed in a temperature-controlled room (22 \u00b0C). OxyHb, deoxyHb, and O\n                      <jats:sub>2<\/jats:sub>\n                      sat values were calculated for 78-mm\n                      <jats:sup>2<\/jats:sup>\n                      regions of interest for the ventral fingertips and palm (for normalization). Subjects underwent a cold provocation challenge (gloved hand submersion in 15 \u00b0C water bath for 1 min), and repeated HSI was performed at 0, 10, and 20 min. Patients completed two patient-reported outcome (PRO) instruments: the Raynaud Condition Score (RCS) and the Cochin Hand Function Scale (CHFS) for symptom burden assessment. Statistical analyses were performed using the Mann-Whitney\n                      <jats:italic>U<\/jats:italic>\n                      test and a mixed effects model (Stata, College Station, TX).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety-two percent of participants were women in their 40s. For SSc-RP patients, 69% had limited cutaneous SSc, the mean \u00b1 SD SSc duration was 11 \u00b1 5 years, and 38% had prior digital ulcers\u2014none currently. Baseline deoxyHb was higher, and O\n                      <jats:sub>2<\/jats:sub>\n                      sat was lower, in SSc patients versus HC (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05). SSc patients had a greater decline in oxyHb and O\n                      <jats:sub>2<\/jats:sub>\n                      sat from baseline to time 0 (after cold challenge) with distinct rewarming oxyHb, O\n                      <jats:sub>2<\/jats:sub>\n                      sat, and deoxyHb trajectories versus HCs (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01). There were no significant correlations between oxyHb, deoxyHb, and O\n                      <jats:sub>2<\/jats:sub>\n                      sat level changes following cold challenge and RCS or CHFS scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hyperspectral imaging is a feasible approach for SSc-RP quantification in the clinic setting. The RCS and CHFS values did not correlate with HSI parameters. Our data suggest that HSI technology for the assessment of SSc-RP at baseline and in response to cold provocation is a potential quantitative measure for SSc-RP severity and activity, though longitudinal studies that assess sensitivity to change are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-023-02990-3","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T19:06:49Z","timestamp":1674241609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon"],"prefix":"10.1186","volume":"25","author":[{"given":"Shannon","family":"Teaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Perry","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Sumpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bauer E.","family":"Sumpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8652-9890","authenticated-orcid":false,"given":"Monique","family":"Hinchcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"12","key":"2990_CR1","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s10067-019-04745-5","volume":"38","author":"JD Pauling","year":"2019","unstructured":"Pauling JD, Hughes M, Pope JE. Raynaud\u2019s phenomenon-an update on diagnosis, classification and management. Clin Rheumatol. 2019;38(12):3317\u201330.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2990_CR2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3899\/jrheum.151018","volume":"43","author":"V Smith","year":"2016","unstructured":"Smith V, Pizzorni C, Riccieri V, Decuman S, Brusselle G, Pauw MDE, et al. Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: an open-label study. J Rheumatol. 2016;43(5):995\u20136.","journal-title":"J Rheumatol"},{"issue":"6","key":"2990_CR3","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/annrheumdis-2015-208857","volume":"75","author":"V Lambrecht","year":"2016","unstructured":"Lambrecht V, Cutolo M, De Keyser F, Decuman S, Ruaro B, Sulli A, et al. Reliability of the quantitative assessment of peripheral blood perfusion by laser speckle contrast analysis in a systemic sclerosis cohort. Ann Rheum Dis. 2016;75(6):1263\u20134.","journal-title":"Ann Rheum Dis"},{"key":"2990_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejim.2021.01.022","volume":"87","author":"C Bruni","year":"2021","unstructured":"Bruni C, Cometi L, Gigante A, Rosato E, Matucci-Cerinic M. Prediction and primary prevention of major vascular complications in systemic sclerosis. Eur J Intern Med. 2021;87:51\u20138.","journal-title":"Eur J Intern Med"},{"issue":"12","key":"2990_CR5","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/rheumatology\/kel337","volume":"45","author":"AH Mawdsley","year":"2006","unstructured":"Mawdsley AH. Patient perception of UK scleroderma services--results of an anonymous questionnaire. Rheumatology (Oxford). 2006;45(12):1573.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"2990_CR6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/rheumatology\/kev002","volume":"54","author":"M Hughes","year":"2015","unstructured":"Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL. Prediction and impact of attacks of Raynaud\u2019s phenomenon, as judged by patient perception. Rheumatology (Oxford). 2015;54(8):1443\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2990_CR7","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00296-015-3241-1","volume":"35","author":"G de la Pe\u00f1a","year":"2015","unstructured":"de la Pe\u00f1a G, Lefebvre P, Nishishinya MB, Pereda CA, Loza E, Sifuentes Giraldo WA, et al. Efficacy of Raynaud\u2019s phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int. 2015;35(9):1447\u201359.","journal-title":"Rheumatol Int"},{"issue":"6","key":"2990_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/BOR.0000000000000332","volume":"28","author":"AL Herrick","year":"2016","unstructured":"Herrick AL. Recent advances in the pathogenesis and management of Raynaud\u2019s phenomenon and digital ulcers. Curr Opin Rheumatol. 2016;28(6):577\u201385.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"2990_CR9","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/art.10486","volume":"46","author":"PA Merkel","year":"2002","unstructured":"Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon. Arthritis Rheum. 2002;46(9):2410\u201320.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2990_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/ard.2009.107706","volume":"69","author":"PP Khanna","year":"2010","unstructured":"Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud\u2019s condition score in patients with Raynaud\u2019s phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis. 2010;69(3):588\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2990_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/2397198318774307","volume":"3","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, et al. Patient-reported outcome instruments for assessing Raynaud\u2019s phenomenon in systemic sclerosis: a SCTC vascular working group report. J Scleroderma Relat Disord. 2018;3(3):249\u201352.","journal-title":"J Scleroderma Relat Disord"},{"issue":"3","key":"2990_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.24333","volume":"60","author":"AL Herrick","year":"2009","unstructured":"Herrick AL, Roberts C, Tracey A, Silman A, Anderson M, Goodfield M, et al. Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. Arthritis Rheum. 2009;60(3):878\u201382.","journal-title":"Arthritis Rheum"},{"issue":"9498","key":"2990_CR13","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0140-6736(05)67696-9","volume":"366","author":"RL Greenman","year":"2005","unstructured":"Greenman RL, Panasyuk S, Wang X, Lyons TE, Dinh T, Longoria L, et al. Early changes in the skin microcirculation and muscle metabolism of the diabetic foot. Lancet. 2005;366(9498):1711\u20137.","journal-title":"Lancet."},{"issue":"6","key":"2990_CR14","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jvs.2011.06.022","volume":"54","author":"JA Chin","year":"2011","unstructured":"Chin JA, Wang EC, Kibbe MR. Evaluation of hyperspectral technology for assessing the presence and severity of peripheral artery disease. J Vasc Surg. 2011;54(6):1679\u201388.","journal-title":"J Vasc Surg"},{"issue":"12","key":"2990_CR15","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2174\/1381612824666180302141902","volume":"24","author":"OA Mennes","year":"2018","unstructured":"Mennes OA, van Netten JJ, Slart R, Steenbergen W. Novel optical techniques for imaging microcirculation in the diabetic foot. Curr Pharm Des. 2018;24(12):1304\u201316.","journal-title":"Curr Pharm Des"},{"issue":"11","key":"2990_CR16","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.2337\/dc08-2246","volume":"32","author":"A Nouvong","year":"2009","unstructured":"Nouvong A, Hoogwerf B, Mohler E, Davis B, Tajaddini A, Medenilla E. Evaluation of diabetic foot ulcer healing with hyperspectral imaging of oxyhemoglobin and deoxyhemoglobin. Diabetes Care. 2009;32(11):2056\u201361.","journal-title":"Diabetes Care"},{"issue":"4","key":"2990_CR17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jvs.2016.03.463","volume":"64","author":"BJ Sumpio","year":"2016","unstructured":"Sumpio BJ, Citoni G, Chin JA, Sumpio BE. Use of hyperspectral imaging to assess endothelial dysfunction in peripheral arterial disease. J Vasc Surg. 2016;64(4):1066\u201373.","journal-title":"J Vasc Surg"},{"issue":"6","key":"2990_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.avsg.2010.03.005","volume":"24","author":"L Jafari-Saraf","year":"2010","unstructured":"Jafari-Saraf L, Gordon IL. Hyperspectral imaging and ankle: brachial indices in peripheral arterial disease. Ann Vasc Surg. 2010;24(6):741\u20136.","journal-title":"Ann Vasc Surg"},{"issue":"11","key":"2990_CR19","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2990_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMra1507638","volume":"375","author":"FM Wigley","year":"2016","unstructured":"Wigley FM, Flavahan NA. Raynaud\u2019s phenomenon. N Engl J Med. 2016;375(6):556\u201365.","journal-title":"N Engl J Med"},{"key":"2990_CR21","doi-asserted-by":"crossref","unstructured":"Cutolo M. Atlas of capillaroscopy in rheumatic diseases: Elsevier srl; 2015.","DOI":"10.1007\/978-1-4939-1526-2_12"},{"issue":"3","key":"2990_CR22","doi-asserted-by":"publisher","first-page":"102458","DOI":"10.1016\/j.autrev.2020.102458","volume":"19","author":"V Smith","year":"2020","unstructured":"Smith V, Herrick AL, Ingegnoli F, Damjanov N, De Angelis R, Denton CP, et al. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud\u2019s phenomenon and systemic sclerosis. Autoimmun Rev. 2020;19(3):102458.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"2990_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/art.40457","volume":"70","author":"JD Wilkinson","year":"2018","unstructured":"Wilkinson JD, Leggett SA, Marjanovic EJ, Moore TL, Allen J, Anderson ME, et al. A multicenter study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud\u2019s phenomenon. Arthritis Rheum. 2018;70(6):903\u201311.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2990_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/art.22468","volume":"57","author":"F Rannou","year":"2007","unstructured":"Rannou F, Poiraudeau S, Berezn\u00e9 A, Baubet T, Le-Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin hand function scale, health assessment questionnaire (HAQ), systemic sclerosis HAQ, and medical outcomes study 36-item short form health survey. Arthritis Rheum. 2007;57(1):94\u2013102.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2990_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/1529-0131(200010)13:5<296::AID-ANR9>3.0.CO;2-F","volume":"13","author":"S Poiraudeau","year":"2000","unstructured":"Poiraudeau S, Lefevre-Colau MM, Fermanian J, Revel M. The ability of the Cochin rheumatoid arthritis hand functional scale to detect change during the course of disease. Arthritis Care Res. 2000;13(5):296\u2013303.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"2990_CR26","doi-asserted-by":"publisher","first-page":"101474","DOI":"10.1016\/j.berh.2019.101474","volume":"34","author":"AL Herrick","year":"2020","unstructured":"Herrick AL, Wigley FM. Raynaud\u2019s phenomenon. Best Pract Res Clin Rheumatol. 2020;34(1):101474.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"2990_CR27","first-page":"18","volume":"41","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Sulli A, Pizzorni C, Paolino S, Smith V. Systemic sclerosis: markers and targeted treatments. Acta Reumatol Port. 2016;41(1):18\u201325.","journal-title":"Acta Reumatol Port"},{"issue":"5","key":"2990_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/imj.12082","volume":"43","author":"P Sinnathurai","year":"2013","unstructured":"Sinnathurai P, Schrieber L. Treatment of Raynaud phenomenon in systemic sclerosis. Intern Med J. 2013;43(5):476\u201383.","journal-title":"Intern Med J"},{"issue":"3","key":"2990_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/10739689709146797","volume":"4","author":"IM Braverman","year":"1997","unstructured":"Braverman IM. The cutaneous microcirculation: ultrastructure and microanatomical organization. Microcirculation. 1997;4(3):329\u201340.","journal-title":"Microcirculation."},{"issue":"Pt 3","key":"2990_CR30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1113\/jphysiol.2002.037994","volume":"549","author":"W Wang","year":"2003","unstructured":"Wang W, Winlove CP, Michel CC. Oxygen partial pressure in outer layers of skin of human finger nail folds. J Physiol. 2003;549(Pt 3):855\u201363.","journal-title":"J Physiol"},{"issue":"5","key":"2990_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/rheumatology\/keh552","volume":"44","author":"AL Herrick","year":"2005","unstructured":"Herrick AL. Pathogenesis of Raynaud\u2019s phenomenon. Rheumatology (Oxford). 2005;44(5):587\u201396.","journal-title":"Rheumatology (Oxford)"},{"issue":"6 Suppl 86","key":"2990_CR32","first-page":"S-154-60","volume":"32","author":"RT Domsic","year":"2014","unstructured":"Domsic RT, Dezfulian C, Shoushtari A, Ivanco D, Kenny E, Kwoh CK, et al. Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-154-60.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2990_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/08916939908994064","volume":"31","author":"MB Kahaleh","year":"1999","unstructured":"Kahaleh MB, LeRoy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity. 1999;31(3):195\u2013214.","journal-title":"Autoimmunity."},{"issue":"4","key":"2990_CR34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0889-857X(05)70295-7","volume":"22","author":"EC LeRoy","year":"1996","unstructured":"LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin N Am. 1996;22(4):675\u201394.","journal-title":"Rheum Dis Clin N Am"},{"issue":"2","key":"2990_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0889-857X(03)00021-8","volume":"29","author":"NA Flavahan","year":"2003","unstructured":"Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud\u2019s phenomenon and scleroderma. Rheum Dis Clin N Am. 2003;29(2):275\u201391 vi.","journal-title":"Rheum Dis Clin N Am"},{"issue":"5","key":"2990_CR36","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/1529-0131(199905)42:5<930::AID-ANR11>3.0.CO;2-1","volume":"42","author":"VS Rajkumar","year":"1999","unstructured":"Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynaud\u2019s phenomenon and systemic sclerosis. Arthritis Rheum. 1999;42(5):930\u201341.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2990_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000339035","volume":"30","author":"A Giovannetti","year":"2012","unstructured":"Giovannetti A, Gambardella L, Pietraforte D, Rosato E, Giammarioli AM, Salsano F, et al. Red blood cell alterations in systemic sclerosis: a pilot study. Cell Physiol Biochem. 2012;30(2):418\u201327.","journal-title":"Cell Physiol Biochem"},{"issue":"7","key":"2990_CR38","first-page":"1268","volume":"21","author":"R Vancheeswaran","year":"1994","unstructured":"Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol. 1994;21(7):1268\u201376.","journal-title":"J Rheumatol"},{"issue":"1","key":"2990_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/1523-1747.ep12360103","volume":"101","author":"GA Knock","year":"1993","unstructured":"Knock GA, Terenghi G, Bunker CB, Bull HA, Dowd PM, Polak JM. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud\u2019s phenomenon and systemic sclerosis. J Invest Dermatol. 1993;101(1):73\u20138.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2990_CR40","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","volume":"34","author":"LS Teh","year":"1995","unstructured":"Teh LS, Manning J, Moore T, Tully MP, O\u2019Reilly D, Jayson MI. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud\u2019s phenomenon. Br J Rheumatol. 1995;34(7):636\u201341.","journal-title":"Br J Rheumatol"},{"issue":"9075","key":"2990_CR41","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(05)64133-5","volume":"350","author":"F Khan","year":"1997","unstructured":"Khan F, Greig IR, Newton DJ, Butler AR, Belch JJ. Skin blood flow after transdermal S-nitrosothio-acetylglucose. Lancet. 1997;350(9075):410\u20131.","journal-title":"Lancet."},{"issue":"8730","key":"2990_CR42","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/0140-6736(90)93307-B","volume":"336","author":"CB Bunker","year":"1990","unstructured":"Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud\u2019s phenomenon. Lancet. 1990;336(8730):1530\u20133.","journal-title":"Lancet."},{"issue":"3","key":"2990_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s10067-003-0698-1","volume":"22","author":"YT Konttinen","year":"2003","unstructured":"Konttinen YT, Mackiewicz Z, Ruuttila P, Ceponis A, Sukura A, Povilenaite D, et al. Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol. 2003;22(3):196\u2013202.","journal-title":"Clin Rheumatol"},{"key":"2990_CR44","volume-title":"Raynaud disease. StatPearls","author":"R Musa","year":"2022","unstructured":"Musa R, Qurie A. Raynaud disease. StatPearls. Treasure Island: StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC; 2022."},{"issue":"6 Suppl 86","key":"2990_CR45","first-page":"S-53-9","volume":"32","author":"TK Bergersen","year":"2014","unstructured":"Bergersen TK, Hoffmann-Vold AM, Midtvedt \u00d8, Gran JT, M\u00f8rk C, Toska K, et al. Dysfunctional arteriovenous anastomoses in hands of systemic sclerosis patients with digital ulcers. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-53-9.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"2990_CR46","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3899\/jrheum.141437","volume":"42","author":"JD Pauling","year":"2015","unstructured":"Pauling JD, Shipley JA, Hart DJ, McGrogan A, McHugh NJ. Use of laser speckle contrast imaging to assess digital microvascular function in primary Raynaud phenomenon and systemic sclerosis: a comparison using the Raynaud condition score diary. J Rheumatol. 2015;42(7):1163\u20138.","journal-title":"J Rheumatol"},{"issue":"1","key":"2990_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.rdc.2007.11.006","volume":"34","author":"A Herrick","year":"2008","unstructured":"Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin N Am. 2008;34(1):89\u2013114 vii.","journal-title":"Rheum Dis Clin N Am"},{"issue":"8","key":"2990_CR48","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s10067-006-0489-6","volume":"26","author":"M Baron","year":"2007","unstructured":"Baron M, Bell M, Bookman A, Buchignani M, Dunne J, Hudson M, et al. Office capillaroscopy in systemic sclerosis. Clin Rheumatol. 2007;26(8):1268\u201374.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2990_CR49","first-page":"754","volume":"25","author":"M Hudson","year":"2007","unstructured":"Hudson M, Taillefer S, Steele R, Dunne J, Johnson SR, Jones N, et al. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol. 2007;25(5):754\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 3","key":"2990_CR50","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.5152\/eurjrheum.2020.19124","volume":"7","author":"AL Herrick","year":"2020","unstructured":"Herrick AL, Dinsdale G, Murray A. New perspectives in the imaging of Raynaud\u2019s phenomenon. Eur J Rheumatol. 2020;7(Suppl 3):S212\u2013s21.","journal-title":"Eur J Rheumatol"},{"issue":"1","key":"2990_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.47.1.43","volume":"47","author":"NJ McHugh","year":"1988","unstructured":"McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud\u2019s phenomenon in systemic sclerosis. Ann Rheum Dis. 1988;47(1):43\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2990_CR52","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/00005344-198705000-00018","volume":"9","author":"RJ Gush","year":"1987","unstructured":"Gush RJ, Taylor LJ, Jayson MI. Acute effects of sublingual nifedipine in patients with Raynaud\u2019s phenomenon. J Cardiovasc Pharmacol. 1987;9(5):628\u201331.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"2990_CR53","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.semarthrit.2020.06.018","volume":"50","author":"JD Pauling","year":"2020","unstructured":"Pauling JD, Hackett N, Guida A, Merkel PA. Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: a systematic literature review. Semin Arthritis Rheum. 2020;50(5):1114\u201330.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2990_CR54","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/annrheumdis-2013-203514","volume":"73","author":"B Ruaro","year":"2014","unstructured":"Ruaro B, Sulli A, Alessandri E, Pizzorni C, Ferrari G, Cutolo M. Laser speckle contrast analysis: a new method to evaluate peripheral blood perfusion in systemic sclerosis patients. Ann Rheum Dis. 2014;73(6):1181\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2990_CR55","doi-asserted-by":"publisher","first-page":"e0174703","DOI":"10.1371\/journal.pone.0174703","volume":"12","author":"J Z\u00f6tterman","year":"2017","unstructured":"Z\u00f6tterman J, Mirdell R, Horsten S, Farnebo S, Tesselaar E. Methodological concerns with laser speckle contrast imaging in clinical evaluation of microcirculation. PLoS One. 2017;12(3):e0174703.","journal-title":"PLoS One"},{"issue":"7","key":"2990_CR56","first-page":"1630","volume":"30","author":"PA Merkel","year":"2003","unstructured":"Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol. 2003;30(7):1630\u201347.","journal-title":"J Rheumatol"},{"key":"2990_CR57","unstructured":"Pauling JD, Shipley JA, Hart D, Milne GL, McHugh NJ. Evaluating the effects of combination aspirin and dipyridamole (Asasantin retard) on platelet function, oxidative stress and peripheral vascular function in primary Raynaud\u2019s phenomenon and systemic sclerosis. Arthritis Rheum. 2013;65:S299."},{"issue":"4","key":"2990_CR58","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/acr.21858","volume":"65","author":"H Gladue","year":"2013","unstructured":"Gladue H, Maranian P, Paulus HE, Khanna D. Evaluation of test characteristics for outcome measures used in Raynaud\u2019s phenomenon clinical trials. Arthritis Care Res. 2013;65(4):630\u20136.","journal-title":"Arthritis Care Res"},{"key":"2990_CR59","doi-asserted-by":"crossref","unstructured":"Yu L, Domsic RT, Saketkoo LA, Withey J, Frech TM, Herrick AL, et al. The assessment of systemic sclerosis-associated Raynaud\u2019s phenomenon (ASRAP) questionnaire: item bank and short form development. Arthritis Care Res 2022.","DOI":"10.1002\/acr.25038"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-02990-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-02990-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-02990-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T16:51:35Z","timestamp":1679417495000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-02990-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2990"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-02990-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"1 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Yale University Human Investigation Committee (HIC# 2000026608). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}